
Hidden Sensors Reveal Filthy Truth About Handwashing in Hospital Bathrooms
Scientists from the University of Surrey in England led the study, installing sensors near hospital toilet and sink pipes to keep track of people's handwashing. Nearly half of toilet users skipped the sink after flushing, they found. The researchers say more effective strategies are needed to remind and convince people of the importance of handwashing, particularly in high-risk environments like hospitals.
Scientists Capture the Spray From a Flushing Toilet in All Its Disgusting Glory
Previous studies have tried to analyze how rigorous people are about handwashing in hospitals and other settings, but they've been limited. Some have relied on asking people to self-report their hygiene habits, for instance, which might incentivize more than a few to fudge the truth. The researchers decided to take a different approach. They connected sensors to toilet and sink pipes that could objectively and non-intrusively detect if and when they were being used. The sensors work by measuring the temperature in the pipes and nearby air; when either cold or hot water passes through the pipes, the temperature sharply changes relative to its surroundings, indicating use.
The researchers teamed up with the Bispebjerg Hospital in Denmark to conduct their study (aptly named the 'FLUSH. WASH. PROTECT.' study). For 19 weeks, they tracked people's handwashing behaviors at two public restrooms in the hospital, ultimately recording more than 2,600 flushes. Nearly 44% of the time after flushing, people steered clear of handwashing. At times, non-adherence was even worse, with over 60% of people not handwashing during certain weeks. Non-handwashing was also more common at the start and end of the day and during typical meal times. The team released its findings last week on the Open Source Framework.
'People may assume handwashing is second nature by now—especially in hospitals and post-covid-19—but our data paints a different picture,' said lead author Pablo Pereira-Doel, co-leader of the Human Insight Lab at the University of Surrey's Business School, in a statement from the university.
Mosquitoes Have Mixed Feelings About Soap, Study Finds
Low rates of handwashing can, of course, make it easier for doctors, patients, and visitors to inadvertently spread dangerous infections to already vulnerable people, including drug-resistant superbugs. Some studies have suggested that certain interventions, like clear signs, can modestly boost handwashing at hospitals, at least temporarily. But given the results here, it's likely we'll need to do a lot more to consistently improve people's hand hygiene.
'These findings are worrying but not surprising. Even simple behaviors like handwashing can lapse without reinforcement. In hospitals, lapses like these can have serious consequences—for patients and for the wider healthcare system. It's time we moved beyond posters and hand gel stations to more effective behavioral strategies,' said study author Carrie Newlands, Lead for Clinical Skills at the University of Surrey's School of Medicine, in a statement.
In the meantime, I wouldn't blame you (or myself) for avoiding the standard handshake more often. And just in case anyone needs it, here's the proper technique for handwashing, courtesy of the Centers for Disease Control and Prevention.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
11 minutes ago
- Medscape
Long COVID Gene Variants: A Step Toward a Diagnostic Test?
A large-scale global study has identified genetic variants that are risk factors for long COVID, a discovery that helps researchers better understand the biological systems involving the disease and one small, early step toward the elusive goal of developing a long COVID diagnostic test. International researchers with the Long COVID Host Genetics Initiative used data from 33 independent studies and 19 countries across North America, Europe, the Middle East, and Asia to analyze the genomes of nearly 16,000 patients with long COVID, representing populations from six genetic ancestries. Nearly 1.9 million controls were included in the genome-wide association study, a research method that scans complete sets of DNA to identify genetic variations associated with a specific trait or disease. Genetic variants found in the FOXP4 gene had a statistically significant risk linked to long COVID, the study, published in Nature Genetics , found. The FOXP4 gene is known to impact lung function, and its expression levels were higher in those with long COVID than in controls. In addition, the risk variants had a consistent effect across different ancestries. The researchers also found a causal relationship between a SARS-CoV-2 infection and long COVID and an additional causal risk between infections severe enough to require hospitalization and long COVID. Researchers also analyzed possible connections between variants associated with long COVID and those linked to other diseases and conditions. Scientists said the overall findings provided evidence that was consistent with long COVID research that suggests both individual genetic variants and environmental risk factors contribute to disease risk. The findings also provide genetic proof linking abnormal lung physiology and the development of long COVID, the authors concluded; however, they noted that long COVID symptoms are not only limited to lung function and may include fatigue and cognitive dysfunction as well. The study's co-author, Hanna Ollila, PhD, with the Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland, underscored that the newly discovered genetic variants were not predictive for clinical tests or personal disease risk. 'The findings from our study, and from genome-wide association studies in general, tell about biological mechanisms behind a disease. This can then help to understand the disease better. For example, is it a disease neuronal, immune, metabolic, and so on?' said Ollila, who is also a researcher with the Department of Anesthesia and Center for Genomic Medicine at Massachusetts General Hospital, Boston. There are still many steps between these types of discoveries and the development of a diagnostic test, she explained, since these types of genetic variants do not function like high-impact variants such as the BRCA mutations in breast cancer. 'In other words, they do not strongly predict whether someone will develop long COVID at the individual level,' Ollila said. 'Instead, they highlight the biological systems involved in the disease. In this case, our findings point to immune pathways related to lung function.' Ollila explained that genetics can guide diagnostic development by pointing to underlying mechanisms, which may then help identify biomarkers in blood or other tissues. These biomarkers could eventually contribute to diagnostic tools, but it is a process that takes time and collaboration and often depends on progress across several fields of research including imaging and clinical phenotyping. Researchers hope that when larger sample sizes become available for bigger studies, the analyses and understanding of the correlations will become more precise, bringing more understanding and clarity on genetic risk factors, biological mechanisms, and biomarkers that could someday help with disease diagnosis. 'We are likely still several years away, and possibly even a decade or more, from having a clinically useful diagnostic test based on genetic or biological markers for long COVID,' said Ollila. 'That said, progress is accelerating thanks to the growing number of well-characterized cohorts and international collaborations. While these genetic findings are not yet ready for clinical application, they are an important step toward understanding long COVID, its relationship with other diseases, and the disease mechanisms that modulate risk for long COVID.'
Yahoo
an hour ago
- Yahoo
Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Growth
The global cancer diagnostics market, valued at USD 23.84 billion in 2024, is forecasted to grow at an 11.5% CAGR, reaching USD 70.80 billion by 2034. Key drivers include rising cancer cases, early detection initiatives, and technological advances like AI and liquid biopsies. The robust market includes leaders like Roche, Thermo Fisher, and expanding regions such as North America. Cancer Diagnostics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Cancer Diagnostics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)" report has been added to global cancer diagnostics market was valued at USD 23.84 Billion in 2024, driven by the rising prevalence of cancer and increasing awareness and early detection initiatives across the globe. The market is anticipated to grow at a CAGR of 11.50% during the forecast period of 2025-2034, with the values likely to reach USD 70.80 Billion by 2034 . Cancer diagnostics involves identifying cancer early to improve treatment outcomes. It typically starts with a clinical evaluation, including physical exams and medical history reviews. Diagnostic tests like imaging (X-rays, CT scans, MRIs, PET scans) detect abnormalities, while blood tests identify cancer markers. Biopsies, where tissue samples are examined under a microscope, confirm malignancy and provide detailed information about the tumour. Advanced methods, such as molecular testing, identify genetic mutations to guide personalised treatments. Screening programmes, like mammograms and colonoscopies, help detect cancer in its early stages. Accurate diagnostics are essential for effective treatment planning and monitoring of disease Diagnostics Market Growth Drivers Rising Merger and Acquisition Activities to Accelerate Market GrowthIncreasing demand for specialised cancer diagnostics and expanding healthcare access in emerging regions are major drivers of growth in the market. For instance, in December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India. With Core Diagnostics' extensive oncology portfolio and its established network of 200 cities, this move will drive market expansion and enhance diagnostic capabilities. The deal is set to propel Metropolis into a leading position, stimulating market growth in the forecast period by offering advanced cancer diagnostics to a wider Fundings and Investments to Meet Rising Cancer Diagnostics Market DemandGrowing investments in innovative cancer therapies and advancements in radiotherapy are key drivers for the expanding market. For instance, in November 2024, ARC Innovation, part of Sheba Medical Center, secured USD 5.1 million in funding for Starget Pharma, a startup developing targeted radioligand therapies for precise cancer diagnosis and treatment. With funding from the Cancer Focus fund, supported by MD Anderson Cancer Center, Starget Pharma plans to conduct clinical trials on cancers such as sarcomas and melanoma. This breakthrough in cancer diagnostics and treatment will likely enhance the efficacy of therapies and offer new diagnostic tools, positioning this technology to significantly impact the global market in the forecast Diagnostics Market TrendsAdvanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Market GrowthThe market is experiencing the rapid adoption of liquid biopsy technologies, which enable the detection of genetic mutations and biomarkers through blood samples. These non-invasive diagnostic tools are revolutionizing cancer detection by offering early diagnosis and real-time monitoring of treatment response. Liquid biopsy's increased accuracy and reduced patient discomfort are contributing to its growing popularity, particularly in precision oncology. As healthcare systems focus on improving early cancer detection, this technology's market demand is expected to rise significantly. Furthermore, advancements in molecular biology and bioinformatics will further boost its integration into clinical practice, expanding its market of Advanced Technologies to Impact the Cancer Diagnostics Market Value PositivelyArtificial intelligence (AI) and machine learning (ML) are playing a pivotal role in transforming the global cancer diagnostics market. AI-powered diagnostic tools enhance the accuracy of medical imaging, enabling early-stage cancer identification through pattern recognition and predictive analytics. These technologies not only improve diagnostic precision but also streamline workflow efficiencies, reduce human errors, and enhance treatment outcomes. With substantial investments being poured into AI in healthcare, the demand for AI-driven diagnostic solutions is growing. As the technology continues to evolve, its integration into cancer diagnostics will significantly increase market growth, driving future market value and development in the healthcare Partnerships Poised to Drive Cancer Diagnostics Market GrowthThe growing demand for precise and personalised cancer diagnostics is driving strategic collaborations in the field. For instance, in August 2024, Hitachi High-Tech Corporation and Gencurix, Inc. formed a partnership to develop cancer molecular diagnostics. By combining Hitachi's expertise in in vitro diagnostics and digital technologies with Gencurix's proficiency in biomarker discovery, the two companies aim to create advanced testing services. After a successful feasibility study, both companies are now set to commercialise these services in Japan. This collaboration will likely enhance the availability of molecular testing for cancer diagnosis, accelerating the growth of the global cancer diagnostics market by offering cutting-edge, more accurate diagnostic of Next-Generation Sequencing Technology to Increase Cancer Diagnostics Market SizeNext-generation sequencing (NGS) is a breakthrough technology that is rapidly transforming the global cancer diagnostics market. NGS offers high-throughput genomic analysis, enabling comprehensive testing of cancerous tissues to identify genetic mutations and potential therapeutic targets. This technology facilitates early detection of cancer, personalized treatment planning, and monitoring of therapeutic efficacy, contributing to better patient outcomes. The increasing availability of cost-effective NGS platforms and advancements in bioinformatics are driving its integration into clinical oncology practices. As a result, the NGS segment within the cancer diagnostics market is expected to experience substantial growth, adding significant value to the overall market. Key Questions Answered in the Cancer Diagnostics Market What was the global cancer diagnostics market value in 2024? What is the cancer diagnostics market forecast outlook for 2025-2034? What is market segmentation based on technology? How is the market segmented based on application? How is the market segmented based on clinical positioning? What are the major factors aiding the global cancer diagnostics market demand? How has the market performed so far and how is it anticipated to perform in the coming years? What are the market's major drivers, opportunities, and restraints? What are the major cancer diagnostics market trends? Which technology will lead the market segment? Which application will lead the market segment? Which clinical positioning will lead the market segment? Who are the key players involved in the cancer diagnostics market? What is the patent landscape of the market? What are the current unmet needs and challenges in the market? How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $23.84 Billion Forecasted Market Value (USD) by 2034 $70.8 Billion Compound Annual Growth Rate 11.5% Regions Covered Global Supplier Landscape Agilent Technologies, Inc. F. Hoffmann-La Roche AG Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Danaher Corporation GE Healthcare Abbott Siemens Healthineers Bio-Rad Laboratories, Inc. Illumina, Inc. PerkinElmer Inc. QIAGEN Hologic, Inc. Myriad Genetics, Inc. Sysmex Corporation NeoGenomics Laboratories, Inc. Foundation Medicine Grail Guardant Tempus Delfi Diagnotics Exact Sciences Corporation Cancer Diagnostics Market SegmentationMarket Breakup by Technology Blood-based Diagnostics In Vitro Diagnostics Immunoassays Histopathology Others Molecular Diagnostics cfDNA Testing DNA Methylation Analysis Gene Sequencing Polymerase Chain Reaction (PCR) In Situ Hybridization Isothermal Nucleic Acid Amplification Technology (INAAT) Microarrays Spectrometry Others Non-blood-based Diagnostics Imaging CT MRI PET Others Biopsy Comparative Analysis Solid Liquid Others Others Market Breakup by Indication Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Cervical Cancer Blood Cancers (Leukemia and Lymphoma) Skin Cancer (Melanoma) Others Market Breakup by Clinical Positioning Screening Early Detection Treatment Guidance Treatment Response Assessment Market Breakup by Region North America Europe Asia Pacific Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cancer Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
COVID-19 Made Our Brains Age Faster
Credit - Yuichiro Chino—Getty Images COVID-19 is leaving all kinds of legacies on our health, both on our bodies and our brains. In a study published July 22 in Nature Communications, researchers report that living through the pandemic aged our brains—whether or not you were infected with COVID-19. To investigate COVID-19's impact on the brain, researchers looked at brain scans from 1,000 people during and before the pandemic. They compared these to brain scans from other people taken during "normal" times as a model for typical brain aging. Led by Ali-Reza Mohammadi-Nejad from the University of Nottingham School of Medicine in the U.K., the researchers looked at measures like brain function, gray and white matter volume, a person's cognitive skills, and their chronological age. Gray matter is critical for memory, emotions, and movement, while white matter is essential for helping nerves transmit electrical signals. The pandemic-era brains aged about 5.5 months faster compared to the brains of those studied before the pandemic. The accelerated aging was documented in people who had COVID-19 infections as well as those who didn't, which strongly suggests that pandemic-related factors other than biological or virus-driven ones—like high stress—were also at work. In fact, the changes in gray and white matter were similar in people who were and were not infected. 'This finding was interesting and rather unexpected,' says Mohammadi-Nejad. Other studies have already shown that the COVID-19 virus can change the brain for the worse, but "we found that participants who simply lived through the pandemic period, regardless of infection, also showed signs of slightly accelerated brain aging. This highlights that the broader experience of the pandemic—including disruptions to daily life, stress, reduced social interactions, reduced activity, etc.,—may have had a measurable impact on brain health.' Read More: What to Know About the New COVID-19 Variant XFG The impact of the pandemic seemed to be greater in certain groups—notably men, the elderly, and people with more compromised health, lower educational status and income, or unstable housing. People with less stable employment had an average of five months of additional brain aging compared to those with higher employment status, while poorer health added about four months of increased brain age compared to better health. However, only people infected with COVID-19 showed drops in cognitive skills. But the fact that those who weren't infected during the pandemic also showed accelerated aging reflects the need to acknowledge the broader health effects of the pandemic beyond the obvious physical metrics on which doctors tend to focus. 'Brain health can be influenced by everyday life activities, and major societal disruptions—like those experienced during the pandemic—can leave a mark even in healthy individuals,' Mohammadi-Nejad says. 'This adds to our understanding of public health by reinforcing the importance of considering mental, cognitive, and social well-being alongside traditional physical health indicators during future crisis-response planning.' While the study did not explore specific ways to address brain aging, he says that strategies known to maintain brain health, such as a healthy diet, exercise, adequate sleep, and social and cognitive interactions are important, especially in the context of stressful circumstances such as a pandemic. 'Whether these can reverse the specific changes we observed remains to be studied,' he says. Contact us at letters@ Solve the daily Crossword